FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Within Our Backyard: Finding Solutions to Overcome Research Resistance November 1, 2017 Amgen Leaps Into the World of Regenerative Medicine With New Investment November 7, 2017 Collegium Announces Additional Managed Care Coverage For Xtampza ER For Medicare Part D Patients May 31, 2017
Collegium Announces Additional Managed Care Coverage For Xtampza ER For Medicare Part D Patients May 31, 2017
